Market Place
Sourcing Support
ARTHEx Biotech Presents ATX-01 Data at TIDES Europe 2024
11 Nov 2024 //
PR NEWSWIRE
ARTHEx Bio Receive FDA Rare Pediatric Designation for ATX-01 in DM1
07 Nov 2024 //
PR NEWSWIRE
ARTHEx Biotech Doses First Patient In Trial For Myotonic Dystrophy
18 Oct 2024 //
PR NEWSWIRE
ARTHEx Receives IND Clearance from FDA to Initiate Phase I-IIa Trial of ATX-01
28 Feb 2024 //
PR NEWSWIRE
ARTHEx Biotech Announces Presentations at OTS and Tides Europe 2023
24 Oct 2023 //
PR NEWSWIRE
ARTHEx Biotech to Present at Chardan`s 7th Annual Genetic Medicines Conference
28 Sep 2023 //
PR NEWSWIRE
ARTHEx Biotech to Present Preclinical Data ATX-01 for Myotonic Dystrophy Ty1
09 May 2023 //
PR NEWSWIRE
ARTHEx nabs Series B for trial of ASO in myotonic dystrophy as Vertex’s deals
03 May 2023 //
ENDPTS
Arthex announces regulatory milestones met in program to develop ATX-01
14 Dec 2022 //
PRNEWSWIRE
Arthex Biotech Appoints Frédéric Legros as Executive Chairman of the Board
28 Nov 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.